Shield Therapeutics Reports $30.4M H1 2026 Revenue, Advances ACCRUFeR® into Phase II PAH Trial in Japan
核心洞察
Shield Therapeutics (搜索) posted H1 2026 total revenues of $30.4 million, up from $21.5 million in H1 2025, driven by a $7.9 million milestone payment from ASK in China and 21% prescription growth.
ACCRUFeR® (ferric maltol) achieved c.102,000 prescriptions dispensed in H1 2026, and the company signed its first Group Purchasing Organisation contract providing access to over 400 clinics.
MEDLEAP Pharma (搜索) enrolled the first patient in a Phase II clinical trial of ferric maltol for pulmonary arterial hypertension (搜索) in Japan, with a planned Phase III trial to follow.
Shield Therapeutics (搜索) plc reported unaudited H1 2026 total revenues of $30.4 million, a significant increase from $21.5 million in the same period of 2025, according to the company's trading update released on 30 July 2026. The growth was fueled by a $7.9 million development milestone payment from Beijing Aosaikang Pharmaceutical (搜索) Co., Ltd. (ASK) in China, higher partner royalties, and a 21% rise in ACCRUFeR® prescriptions dispensed in the United States.
Q2 2026 group net revenues reached $11.9 million, compared to $14.3 million in Q2 2025. ACCRUFeR® net revenues in the US were $10.3 million for the quarter, with an average net price of $208, down from $231 in Q2 2025 — a decline attributed to changes in Prior Authorisation requirements for prescription approvals under New York's Medicaid program.
Commercial Strategy Pivot Drives Prescription Growth
Following the Medicaid PA changes in New York, Shield quickly pivoted its commercial focus toward non-Medicaid business. The company reported 27% growth in H1 2026 compared to H1 2025, with June prescriptions growing 6% month over month. Approximately 49,000 ACCRUFeR® prescriptions were dispensed in Q2 2026, up from roughly 47,000 in Q2 2025. For the first half, total prescriptions reached approximately 102,000, compared to 84,000 in H1 2025.
Anders Lundstrom, Chief Executive Officer of Shield Therapeutics (搜索), commented: "We are pleased with the significant growth in our largest business segment, commercial, which represents two-thirds of total revenue, alongside strong overall prescription growth. Our prior experience in Texas, pivoting from Medicaid to commercial, gives us confidence in this strategy."
The company also signed its first Group Purchasing Organisation (GPO) contract, opening a new channel to market and sell ACCRUFeR® to more than 400 clinics across the United States.
Pipeline Expansion: Ferric Maltol Enters Phase II for PAH in Japan
In a notable pipeline development, MEDLEAP Pharma (搜索), a subsidiary of Vital KSK Holdings (搜索) Inc., confirmed first patient enrollment in a Phase II clinical trial evaluating ACCRUFeR® (ferric maltol) as a treatment for pulmonary arterial hypertension (搜索) (PAH) in Japan. The exploratory study is designed to support a planned Phase III trial and follows confirmation by Japan's Pharmaceuticals and Medical Devices Agency (PMDA) of the development plan for ferric maltol as a PAH therapy, based on prior clinical results from trials conducted in Europe, the UK, and the USA.
Pediatric Indication Extensions Secured Across Key Markets
Shield achieved several regulatory milestones expanding ACCRUFeR®/FeRACCRU® use in pediatric populations. In the United States, the indication extension for pediatric patients 10 years of age and older was launched on 1 April 2026. In Europe, the European Medicines Agency issued a positive opinion on 26 March 2026, followed by the European Commission's decision on 26 May 2026, extending the indication to include patients 12 years and older. The UK's Medicines and Healthcare products Regulatory Agency granted approval for the same pediatric extension on 2 July 2026.
A report titled "Ferric Maltol: Pediatric First Approval" was published in Pediatric Drugs, reinforcing the FDA's approval of the pediatric indication.
Leadership Appointment and Financial Position
Shield announced the appointment of Michael Jensen as Chief Financial Officer, effective 1 September 2026. Jensen brings over 20 years of executive financial leadership experience across the biopharmaceutical, medical device, and healthcare sectors, having previously served as CFO at StimLabs, Synlogic, and Intrinsic Therapeutics, with earlier senior finance roles at Novo Nordisk, Novartis, and Siemens Healthcare Diagnostics.
Cash and cash equivalents stood at $8.3 million as of 30 June 2026, compared to $12.4 million on 31 March 2026, with the decrease primarily driven by working capital and cost management. The company stated it remains on track for profitability in 2026.
Market Context
Iron deficiency (搜索), with or without anemia, affects approximately 20 million people in the United States, representing a $2.3 billion market opportunity. ACCRUFeR® is positioned as the first and only FDA-approved oral iron therapy for iron deficiency and iron deficiency anemia (搜索), and is currently the number one branded prescription oral iron in the US market, according to IQVIA Xponent PlanTrak data. The drug's patent coverage extends until the mid-2030s.